Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2019

Aug 05, 2019

SELL
$219.29 - $241.72 $11.5 Million - $12.6 Million
-52,251 Closed
0 $0
Q1 2019

Apr 29, 2019

SELL
$216.71 - $338.96 $576,665 - $901,972
-2,661 Reduced 4.85%
52,251 $12.4 Million
Q4 2018

Feb 07, 2019

SELL
$278.5 - $352.75 $37,876 - $47,974
-136 Reduced 0.25%
54,912 $16.5 Million
Q3 2018

Oct 23, 2018

SELL
$293.51 - $383.83 $241,265 - $315,508
-822 Reduced 1.47%
55,048 $19.4 Million
Q2 2018

Aug 03, 2018

SELL
$257.52 - $306.91 $145,756 - $173,711
-566 Reduced 1.0%
55,870 $16.2 Million
Q1 2018

May 03, 2018

SELL
$260.13 - $367.91 $294,467 - $416,474
-1,132 Reduced 1.97%
56,436 $15.5 Million
Q4 2017

Jan 23, 2018

SELL
$307.64 - $344.58 $106,751 - $119,569
-347 Reduced 0.6%
57,568 $18.3 Million
Q3 2017

Nov 07, 2017

BUY
$281.15 - $329.69 $16.3 Million - $19.1 Million
57,915
57,915 $18.1 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $20.8B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Terril Brothers, Inc. Portfolio

Follow Terril Brothers, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Terril Brothers, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Terril Brothers, Inc. with notifications on news.